Skip to Content

KRN5500 Approval Status

FDA Approved: No
Brand name: KRN5500
Company: Midatech Pharma US Inc.
Treatment for: Chronic Chemotherapy Induced Peripheral Neuropathy

KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound in development for the treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics in patients with cancer.

Development Status and FDA Approval Process for KRN5500

DateArticle
Jun 16, 2014DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma
Nov 29, 2012DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Designation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide